The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic

The age-adjusted mortality for melanoma in the US was 2.087 × 100 000 in 2018, 2.006 × 100 000 in 2019, 1.996 × 100 000 in 2020, and 2.035 × 100 000 in 2021, respectively. Neither the cumulative variation between the prepandemic and postpandemic period (analysis of variance: f = 0.84; P = 0.359) nor the comparison between the different years achieved statistical significance by the Tukey post-hoc test, except for a marginally significant decline in 2020 compared with 2018 (P = 0.026). In conclusion, the results of this analysis suggest that possible delays in screening opportunity and early management of melanoma that occurred during the first 2 years of the COVID-19 pandemic did not generate a substantial impact on early mortality for this malignancy in the USA.